doi:10.3969/j.issn.1004-583X.2026.08.016

Abstract

CLC Number:

R730.2

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.08.016

https://www.lchc.cn/EN/Y2026/V41/I8/763

References 31

[1]	Kawaguchi K, Asano S. Pathophysiological roles of actin-binding scaffold protein, ezrin[J]. Int J Mol Sci, 2022, 23(6):3246. doi: 10.3390/ijms23063246.
[2]	Vasiliauskas D, Beiter J, Iyer SS, et al. On the mechanism of ezrin activation[J]. Biophys J, 2026:S0006-3495(26)00216-X. doi: 10.1016/j.bpj.2026.03.032.
[3]	Du Y, Bradshaw WJ, Leisner TM, et al. Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease[J]. J Biol Chem, 2023, 299(12):105382. doi: 10.1016/j.jbc.2023.105382.
[4]	Hadad Y, Fracchia A, Babele D, et al. ERM proteins support perinuclear actin rim formation[J]. Front Cell Dev Biol, 2026, 13:1579946. doi: 10.3389/fcell.2025.1579946.
[5]	Shen Y, Zheng X, Qian Y, et al. Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy[J]. Cancer Sci, 2023, 114(6):2386-2399. doi: 10.1111/cas.15788.
[6]	Büdeyri I, Guckelberger O, Oppermann E, et al. Ezrin polarization as a diagnostic marker for circulating tumor cells in hepatocellular carcinoma[J]. Cells, 2024, 14(1):6. doi: 10.3390/cells14010006.
[7]	Qiao J, Tan Y, Liu H, et al. Histone H3K18 and ezrin lactylation promote renal dysfunction in sepsis-associated acute kidney injury[J]. Adv Sci (Weinh), 2024, 11(28):e2307216. doi: 10.1002/advs.202307216.
[8]	Barik GK, Sahay O, Paul D, et al. Ezrin gone rogue in cancer progression and metastasis: An enticing therapeutic target[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(4): 188753. doi: 10.1016/j.bbcan.2022.188753.
[9]	宋璐, 李红燕, 王少芳. 非小细胞肺癌患者Ezrin和Moesin表达及其临床意义[J]. 实用癌症杂志, 2023, 38(9):1425-1428. doi:10.3969/j.issn.1001-5930.2023.09.008.
[10]	Chen M, Pan Y, Liu H, et al. Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1[J]. Cell Oncol (Dordr), 2023, 46(3):571-587. doi: 10.1007/s13402-022-00761-x. pmid: 36580262
[11]	Huang H. Ezrin (EZR) promotes breast cancer progression and drug resistance: Molecular mechanisms involving STAT3 activation[J]. Life Sci, 2026, 390:124250. doi: 10.1016/j.lfs.2026.124250.
[12]	Shalaby MAGA, Dawoud MM, Gadallah MS, et al. Immunohistochemical expression of parathyroid hormone-related protein and ezrin in invasive breast carcinoma of no special type: A retrospective analysis[J]. Diagn Pathol, 2025, 20(1):8. doi: 10.1186/s13000-025-01598-2. pmid: 39827339
[13]	代基强, 野庆松, 白圣凯, 等. 胰腺癌细胞ezrin基因转录调控区及其gRNA靶位点鉴定[J]. 医学研究生学报, 2020, 33(2):133-138.doi:10.16571/j.cnki.1008-8199.2020.02.005.
[14]	Hałas-Wi'sniewska M, Arendt W, Grzanka A, et al. Downregulation of ezrin suppresses migration potential in cervical cancer cells[J]. Pharmaceuticals (Basel), 2024, 18(1):3. doi: 10.3390/ph18010003.
[15]	Zhang Y, Zhao Q, Du J. Regulatory role of ezrin in esophageal cancer progression via the PI3K-AKT signaling pathway[J]. Hereditas, 2025, 162(1):199. doi: 10.1186/s41065-025-00554-w.
[16]	Shi J, Cai J, Kong L, et al. Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin[J]. Front Oncol, 2025, 15:1537528. doi: 10.3389/fonc.2025.1537528.
[17]	Zhang R, Li G, Du M, et al. Effect of Ezrin on regulating trophoblast cell invasion via PKC signaling pathway in unexplained recurrent spontaneous abortion[J]. Reprod Biol, 2022, 22(2):100634. doi: 10.1016/j.repbio.2022.100634.
[18]	Xu WT, Shi LL, Xu J, et al. Ezrin expression in female reproductive tissues: A review of regulation and pathophysiological implications[J]. Front Cell Dev Biol, 2023, 11:1125881. doi: 10.3389/fcell.2023.1125881.
[19]	Yu H, Luo C, Linghu R, et al. Ezrin contributes to the damage of airway epithelial barrier related to diabetes mellitus[J]. J Inflamm Res, 2024, 17:2609-2621. doi: 10.2147/JIR.S449487. pmid: 38689797
[20]	Dai L, Jin Y, Chai J, et al. Deficiency of DEK proto-oncogene alleviates allergic rhinitis by inhibiting RhoA/Ezrin-mediated mitochondrial fission[J]. Animal Model Exp Med, 2025, 8(11):1947-1959. doi: 10.1002/ame2.12523.
[21]	赵妍, 孙耕耘, 尤青海. 埃兹蛋白-根蛋白-膜突蛋白与呼吸系统疾病的相关研究进展[J]. 中华肺部疾病杂志(电子版), 2015, 8(4):475-477. doi:10.3877/cma.j.issn.1674-6902.2015.04.019.
[22]	Lade JM, Andrade MR, Undem C, et al. Hypoxia enhances interactions between Na⁺/H⁺ exchanger isoform 1 and actin filaments via ezrin in pulmonary vascular smooth muscle[J]. Front Physiol, 2023, 14:1108304. doi: 10.3389/fphys.2023.1108304.
[23]	Chellasamy SK, Watson E. Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors[J]. J King Saud Univ Sci, 2022, 34(7):102277. doi: 10.1016/j.jksus.2022.102277.
[24]	Simó-Servat O, Hernández C, Simó R. The ERM complex: A new player involved in diabetes-induced vascular leakage[J]. Curr Med Chem, 2020, 27(18):3012-3022. doi: 10.2174/0929867325666181016162327. pmid: 30332939
[25]	Simó-Servat O, Ramos H, Bogdanov P, et al. ERM complex, a therapeutic target for vascular leakage induced by diabetes[J]. Curr Med Chem, 2022, 29(12):2189-2199. doi: 10.2174/0929867328666210526114417.
[26]	Gholam MF, Alli AA. Dapagliflozin treatment attenuates the interaction between the renal sodium chloride co-transporter and ezrin in hypertensive diabetic db/db mice[J]. Nephron, 2025:1-17. doi: 10.1159/000543336.
[27]	Guo W, Gao H, Pan W, et al. High glucose induces Nox4 expression and podocyte apoptosis through the Smad3/ezrin/PKA pathway[J]. Biol Open, 2021, 10(5):bio055012. doi: 10.1242/bio.055012.
[28]	Giamundo G, Carratù I, Barone C, et al. Loss of Ezrin triggers mitochondrial dysfunction and oxidative stress, associated with neuronal cell death[J]. Cell Death Discov, 2025, 11(1):490. doi: 10.1038/s41420-025-02790-5. pmid: 41145430
[29]	顾杨怡, 徐亭亭, 常岑, 等. 埃兹蛋白在糖脂代谢中作用的研究进展[J]. 中国病理生理杂志, 2025, 41(1):202-208. doi:10.3969/j.issn.1000-4718.2025.01.024.
[30]	Milutinovic M, Lutimba S, Mansour MA. Structural and dynamic insights into podocalyxin-ezrin interaction as a target in cancer progression[J]. J Xenobiot, 2026, 16(1):25. doi: 10.3390/jox16010025.
[31]	Holms RD, Ataullakhanov RI. Ezrin peptide therapy from HIV to COVID: Inhibition of inflammation and amplification of adaptive anti-viral immunity[J]. Int J Mol Sci, 2021, 22(21):11688. doi: 10.3390/ijms222111688.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2026, 41(7): 668-672.
[2]	. [J]. Clinical Focus, 2025, 40(12): 1147-1152.
[3]	. [J]. Clinical Focus, 2025, 40(10): 943-947.
[4]	Tang Xu, Zuo Zhuang, Yang Kai, Zhang Zhiyuan, Wang Qi, Dong Xinchun, Gou Yunjiu. The efficacy and safety of anti-angiogenic drugs combined with chemotherapy in treating malignant pleural mesothelioma: An updated systematic review and meta-analysis [J]. Clinical Focus, 2025, 40(4): 304-312.
[5]	Huang Xingzhou, Zheng Weihua, Zhang Shutong, Chen Yanhao. Clinical efficacy and safety of drug-eluting beads for bronchial artery chemoembolization versus conventional bronchial artery chemoembolization alone for advanced non-small cell lung cancer [J]. Clinical Focus, 2025, 40(3): 243-250.
[6]	Liu Yunfei, Chen Taoli, Wang Yanpeng, Sui Junzhao, Wang Qichuan. Effect of cinobufotalin combined therapy on cancer pain in patients with advanced non-squamous non-small cell lung cancer with Qi-Yin deficiency [J]. Clinical Focus, 2024, 39(12): 1101-1105.
[7]	Wang Jiaqi, Meng Jianbo, Song Xiaoning, Zhang Jinqiao, Zang Meirong, Lu Jiapei, Suo Jing. Clear cell renal cell carcinoma combined with multiple myeloma: A case report and literature review [J]. Clinical Focus, 2024, 39(11): 1021-1025.
[8]	Tian Xin, Zhao Li, Liu Huijing. Renal clear cell carcinoma complicated with multiple myeloma: A case report and literature review [J]. Clinical Focus, 2024, 39(10): 925-928.
[9]	Yi Peng, Li Cuiling, Huang Xinjiang, Zeng Chunhua. Clinical analysis of 5 cases with precocious puberty caused by hypothalamic hamartomas treated with gonadotropin releasing hormone analogues [J]. Clinical Focus, 2024, 39(1): 53-56.
[10]	Tao Jianan, Li Wenqian, Ma Xiuwen, An Qi, Wang Xuehong. Meta-analysis of expression and clinical significance of HER-2 in hepatocellular carcinoma [J]. Clinical Focus, 2023, 38(12): 1067-1072.
[11]	Zhang Na, Sun Yue, Dong Han, Zhao Peng, Yang Xin, Qi Yuan, Wang Lingling. Correlation between the expression level of SPARC and prognosis in patients with non-small cell lung cancer: A meta-analysis [J]. Clinical Focus, 2023, 38(11): 972-978.
[12]	Liu Fei, Lin Zhichun, Yue Jianlan, Yin Liang, Huang Shiming. Meta-analysis of different positron emission tomography/computed tomography imaging agents in the diagnosis of gliomas [J]. Clinical Focus, 2023, 38(4): 302-307.
[13]	He Chendong, Ge Fenglin, Yang Wei. TFEB translocation renal cell carcinoma: A case and literature review [J]. Clinical Focus, 2022, 37(12): 1122-1126.
[14]	Jia Chengbang, Shen Lijuan, Sun Zhigang. The relationship between CEA, CA125 and NSE and the pathological characteristics of patients with NSCLC and the value of combined detection [J]. Clinical Focus, 2022, 37(11): 992-995.
[15]	He Chao, Huang Shaobin. Predicting the risk by FIB-4 on hepatocellular carcinoma in patients with chronic liver disease: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 779-784.